Fierce Biotech1 min read
saveMarrow extracts $120M series B to advance preclinical blood disease therapy
A new biotech targeting blood disorders, aptly called Marrow Therapeutics, has launched with $173 million in combined funding and a preclinical lead program aimed at sickle cell disease and beta thalassemia.
comments(0)
5-min edit window · permanent after that